#COVID-19 vaccine

The second IAS COVID-19 virtual meeting will coincide with the HIV Research for Prevention Conference.

The panel’s goal is to ensure that all coronavirus therapeutics approved by the government are safe and effective for African Americans.

Political pressure to speed introduction of COVID vaccines threatens scientifically proven systems to protect public safety and research.

A small, secret panel of experts have been tasked with reviewing crucial data of coronavirus vaccines that U.S. taxpayers have helped fund.

The trial is evaluating an investigational vaccine from Janssen that may require only one shot.

An estimated 60% of Republicans and 46% of Democrats say they wouldn’t get inoculated if a vaccine was available.

A Gates Foundation report tracks the pandemic’s global devastation—from health care to equality—and highlights a path forward.

FDA weighs whether to resume coronavirus vaccine trial halted due to an adverse event.

A U.K. woman developed spinal inflammation after receiving an adenovirus vector vaccine.

Public health departments are now being told to prepare to distribute COVID-19 vaccines as early as November 1.

An independent review board has the authority to end the trials weeks early if interim results are overwhelmingly positive or negative.

“Will we have a COVID vaccine next year tailored to the obese? No way."

National Academies recommends a four-phased approach to maximize societal benefit by reducing morbidity and mortality.

Vaccine development is proceeding at an unprecedented pace, but could still hit snags on the way to approval.

The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.